Drug intelligence / Profile preview

ANT195

Development stage: Preclinical
Lead developer: Cambium Oncology
Modality: Small Molecules

Overview

ANT195 is a preclinical-stage small molecule therapeutic being developed by Cambium Oncology for the treatment of Acute Myeloid Leukemia (AML). It is designed to target the VIP/VPAC axis, which comprises the Vasoactive Intestinal Peptide (VIP) and its associated G protein-coupled receptors, VPAC1 and VPAC2. This signaling axis is known to play a significant role in the tumor microenvironment, contributing to immune evasion and the proliferation of malignant cells in various hematological and solid tumors. ANT195 aims to modulate this pathway to inhibit leukemic cell growth and survival, representing a targeted approach within Cambium Oncology's core technology platform.

Targets

VIPR2 (Vasoactive intestinal polypeptide receptor 2)VIPR1 (Vasoactive intestinal peptide receptor 1)

Beyond the preview

Go deeper on ANT195.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT195.

Explore the full profile